Abstract:Introduction: Rapid advancements in Next Generation Sequencing (NGS) and bioinformatics tools have allowed physicians to obtain genetic testing results in a more rapid, cost-effective, and comprehensive manner than ever before. Around 50% of pediatric sensorineural hearing loss (SNHL) cases are due to a genetic etiology, thus physicians regularly utilize targeted sequencing panels that identify variants in genes related to SNHL. These panels allow for early detection of pathogenic variants which allows physicians to provide anticipatory guidance to families. Molecular testing does not always reveal a clear etiology due to the presence of multigenic variants with varying classifications, including the presence of Variants of Uncertain Significance (VUS). This study aims to perform a preliminary bioinformatics characterization of patients with variants associated with Type II Usher Syndrome in the presence of other multigenic variants. We also provide an interpretation algorithm for physicians reviewing molecular results with medical geneticists. Methods: Review of records for multigenic and/or VUS results identified several potential subjects of interest. For the purposes of this study, two ADGRV1 compound heterozygotes met inclusion criteria. Sequencing, data processing, and variant calling (the process by which variants are identified from sequence data) was performed at Invitae (San Francisco CA). The preliminary analysis followed the recommendations outlined by the American College of Medical Genetics and Association for Molecular Pathology (ACMG-AMP) in 2015 and 2019. The present study utilizes computational analysis, predictive data, and population data as well as clinical information from chart review and publicly available information in the ClinVar database. Results: Two subjects were identified as compound heterozygotes for variants in the gene ADGRV1 . Subject 1's variants were predicted as deleterious, while Subject 2's variants were predicted as non-deleterious. These results were based on known information of the variants from ClinVar, multiple lines of computational data, population databases, as well as the clinical presentation. Discussion: Early molecular diagnosis through NGS is ideal, as families are then able to access a wide range of resources that will ultimately support the child as their condition progresses. We recommend that physicians build strong relationships with medical geneticists and carefully review their interpretation before making recommendations to families, particularly when addressing the VUS. Reclassification efforts of VUS are supported by studies like ours that provide evidence of pathogenic or benign effects of variants.

VIP-HL: Semi-automated ACMG/AMP Variant Interpretation Platform for Genetic Hearing Loss

Expert specification of the ACMG/AMP variant interpretation guidelines for genetic hearing loss

Resolving the genetic heterogeneity of prelingual hearing loss within one family: Performance comparison and application of two targeted next generation sequencing approaches

DVPred: a disease-specific prediction tool for variant pathogenicity classification for hearing loss

Machine learning-based genetic diagnosis models for hereditary hearing loss by the <i>GJB2, SLC26A4</i> and <i>MT-RNR1</i> variants

Machine learning-based genetic diagnosis models for hereditary hearing loss by the GJB2, SLC26A4 and MT-RNR1 variants

Gene4HL: An Integrated Genetic Database for Hearing Loss

Bioinformatics characterization of variants of uncertain significance in pediatric sensorineural hearing loss

Quantitative thresholds for variant enrichment in 13,845 cases: improving pathogenicity classification in genetic hearing loss

[The updates of the ACMG variant interpretation guidelines affect the pathogenicity determination of OTOF gene variations in patients with auditory neuropathy]

Assessing variants of uncertain significance implicated in hearing loss using a comprehensive deafness proteome

MOLGENIS VIP: an open-source and modular pipeline for high-throughput and integrated DNA variant analysis

Next-generation sequencing facilitates genetic diagnosis and improves the management of patients with hearing loss in clinical practice

Genetic testing for sporadic hearing loss using targeted massively parallel sequencing identifies 10 novel mutations.

Consensus Interpretation of the P.met34thr and P.val37ile Variants in GJB2 by the ClinGen Hearing Loss Expert Panel

Toward Automatic Variant Interpretation: Discordant Genetic Interpretation Across Variant Annotations for ClinVar Pathogenic Variants

A Dominant Variant in the PDE1C Gene is Associated with Nonsyndromic Hearing Loss

Variant Impact Predictor database (VIPdb), version 2: Trends from 25 years of genetic variant impact predictors

DNA Diagnostics of Hereditary Hearing Loss: A Targeted Resequencing Approach Combined with a Mutation Classification System

GDC: An Integrated Resource to Explore the Pathogenesis of Hearing Loss through Genetics and Genomics

Application of SNPscan in Genetic Screening for Common Hearing Loss Genes.